OUR PIPELINE / NANOVAX THERAPEUTICS
Our nanoparticle technology platform is designed to address fundamental challenges in immune activation and therapeutic efficacy, with applications spanning oncology and infectious disease.
CONCEPTUAL VISUALIZATION
Our Pipeline
Oncology is our primary development focus. Our lead program is actively in IND-enabling development; infectious disease applications remain exploratory.
LEAD ONCOLOGY PROGRAM
NVX-101
IND-ENABLING DEVELOPMENT
THERAPEUTIC AREA
Oncology
INITIAL INDICATION
Melanoma
MODALITY
Dual-adjuvant nanoparticle immunotherapy
PLATFORM FOUNDATION
Discovery & Platform Development
PRECLINICAL FOUNDATION
Preclinical Validation
CURRENT STAGE
IND-Enabling Development
PLANNED
Clinical Development
NVX-101 is approximately one-third through IND-enabling development. Clinical development remains a planned objective; this stage does not imply an IND clearance or an ongoing clinical trial.
NVX-101 is NanoVax’s lead therapeutic candidate, designed to overcome key barriers limiting the effectiveness of cancer immunotherapy. The platform utilizes a dual-adjuvant nanoparticle incorporating complementary STING and TLR4 agonists to coordinate innate immune activation and promote robust tumor-specific T-cell responses.
Combined with NanoVax’s prime-pull immunotherapy strategy, NVX-101 is designed to address two critical challenges in solid tumors: generating potent tumor-specific immune responses and promoting the trafficking of activated T cells into the tumor microenvironment.
Our initial development focus is melanoma, with opportunities to expand into additional solid tumor indications.
EARLY RESEARCH / PLATFORM EXPLORATION
Infectious Disease Adjuvant Platform
Program: Infectious Disease Adjuvant Candidate · Therapeutic area: Infectious Disease · Modality: Nanoparticle-based vaccine adjuvant
NanoVax is also exploring the application of its nanoparticle-based immune activation technology as an advanced vaccine adjuvant for infectious disease.
Building on the platform’s ability to engage complementary innate immune pathways, this program aims to develop next-generation adjuvant technologies capable of enhancing vaccine-induced immune responses.
This represents a potential expansion of NanoVax’s underlying technology platform beyond oncology and into broader vaccine applications.
One Platform. Multiple Therapeutic Opportunities.
Our underlying nanoparticle technology has potential applications across multiple therapeutic areas, with oncology as NanoVax’s primary development focus.
PRIMARY DEVELOPMENT FOCUS
Oncology
Therapeutic cancer vaccines and strategies to improve antitumor immunity.
EXPLORATORY OPPORTUNITY
Infectious Disease
Next-generation vaccine adjuvants designed to enhance protective immune responses.
OUR DEVELOPMENT APPROACH
From Scientific Innovation to Therapeutic Development
The following progression describes our development objectives, not completed milestones.
01 / OBJECTIVE
Platform Engineering
Designing nanoparticle systems capable of delivering complementary immunological signals.
02 / OBJECTIVE
Preclinical Validation
Evaluating immune activation, therapeutic efficacy, biodistribution, and safety.
03 / OBJECTIVE
Translational Development
Advancing promising candidates through formulation optimization and IND-enabling studies.
04 / OBJECTIVE
Clinical Translation
Working toward first-in-human evaluation of promising therapeutic candidates.